| Literature DB >> 35574312 |
Wei-Wei Wei1, Huihui Wang1, Hong Zheng1, Jiming Chen1, Ru-Xia Shi1.
Abstract
Objective: Cervical cancer is a common gynecological malignancy. In addition to the open radical hysterectomy (ORH) and laparoscopic radical hysterectomy (LRH), laparoscopic nerve-sparing radical hysterectomy (LNSRH) could be another treatment option since it could preserve urinary, colorectal, and sexual functions. However, LNSRH might result in early cancer metastasis and recurrence due to inadequate tumor resection. Additionally, whether LNSRH should be considered based on perineural invasion (PNI) status remains controversial. To assess different types of hysterectomy on the outcome of early cervical cancer with PIN.Entities:
Keywords: cervical cancer; laparoscopic surgery; nerve-sparing radical hysterectomy; perineural invasion; survival impacts
Year: 2022 PMID: 35574312 PMCID: PMC9103185 DOI: 10.3389/fonc.2022.889862
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738
Figure 1Histological image of perineural invasion (PNI) in cervical squamous cell carcinoma stained with Hematoxylin and eosin (H&E). PNI from small cancer cell clusters is indicated by arrows (magnification, x200). Scale bar: 20μm each grid.
Clinical and histopathological characteristics of study participants.
| Characteristics | LRH group (N = 33) | ORH group (N = 69) | LNSRH group (N = 72) |
|
|---|---|---|---|---|
| Age, years (mean ± SD) | 52.8 ± 8.0 | 52.8 ± 9.1 | 53.2 ± 10.2 | 0.085 |
| FIGO stage, N (%) | 0.920 | |||
| IA | 1 (3.0%) | 0 (0.0%) | 5 (6.9%) | |
| IB1 | 6 (18.2%) | 14 (20.3%) | 9 (12.5%) | |
| IB2 | 11 (33.3%) | 15 (21.8%) | 28 (38.9%) | |
| IB3 | 1 (3.0%) | 9 (13.0%) | 4 (5.5%) | |
| IIA1 | 2 (6.1%) | 7 (10.1%) | 9 (12.5%) | |
| IIA2 | 2 (6.1%) | 5 (7.2%) | 2 (2.8%) | |
| IIIC1 | 9 (27.3%) | 18 (26.1%) | 13 (18.1%) | |
| IIIC2 | 1 (3.0%) | 1 (1.5%) | 2 (2.8%) | |
| Pathology, N (%) | 0.928 | |||
| Squamous cell carcinoma | 30 (90.9%) | 61 (88.4%) | 64 (88. 9%) | |
| Adeno/adenosquamous carcinoma | 3 (9.1%) | 8 (11.6%) | 8 (11.1%) | |
| Histological grade, N (%) | 0.089 | |||
| Well-differentiated | 8 (24.2%) | 14 (20.3%) | 14 (19.4%) | |
| Moderately differentiated | 17 (51.5%) | 33 (47.8%) | 29 (40.3%) | |
| Poorly differentiated | 8 (24.2%) | 22 (31.9%) | 29 (40.3%) | |
| Tumor size, cm (mean ± SD) | 3.5 ± 1.1 | 3.8 ± 1.2 | 3.5 ± 1.3 | 0.642 |
| Depth of invasion | 0.274 | |||
| <1/2 | 13 (39.4%) | 24 (34. 8%) | 30 (41. 7%) | |
| ≥1/2 | 20 (60.6%) | 45 (65.2%) | 42 (58.3%) | |
| LVSI | 0.330 | |||
| Present | 9 (27.3%) | 26 (37.7%) | 29 (40.3%) | |
| Lymph node metastasis | ||||
| Positive | 10 (30.3%) | 19 (27.5%) | 15 (20.8%) | 0.246 |
| Perineural invasion | ||||
| Positive | 2 (6.1%) | 10 (14.5%) | 9 (12.5%) | 0.407 |
| Rejected adjuvant radiation therapy, N (%) * | 3 (14.3%) | 6 (12.0%) | 3 (5.7%) | 0.152 |
| Cancer recurrence | 0 (0.0%) | 4 (66.7%) | 1 (33.3%) |
LVSI, lymphovascular space invasion.
*These patients were considered to have the risk of tumor recurrence and were offered the adjuvant radiation therapy. However, they refused the treatments.
Figure 2Kaplan-Meier survival analyses. (A) Comparisons of disease-free survival (DFS) periods among three groups. (B) Comparisons of overall survival (OS) periods among three groups. There was no statistically significant difference in DFS and OS among the three groups. (C) DFS periods between positive and negative PNI groups. (D) OS periods between positive and negative PNI groups. PNI positive group had lower DHS and OS than the PCI negative group.
Multivariate analysis for disease-free survival and overall survival.
| Variables | Disease-free survival time | Overall survival time |
|---|---|---|
|
|
| |
| FIGO stage, n (%) | 0.216 | 0.258 |
| Depth of invasion | 0.815 | 0.250 |
| LVSI | 0.652 | 0.146 |
| Lymph nodes metastases | 0.000 | 0.000 |
| Type of surgery* | 0.990 | 0.690 |
LVSI, lymphovascular space invasion.
*Types of surgery, open radical hysterectomy, laparoscopic radical hysterectomy, or laparoscopic nerve-sparing radical hysterectomy.